Search results

FatiAbGen International is the Swiss subsidiary of FatiAbGen Inc., established in Korea in 2020. We engineer best in class antibodies tailored for multiple modalities such as ADCs and bi-specifics. We then develop targeted molecules to address high unmet need diseases in oncology and immunology.

NewBiologix is a company developing a proprietary and breakthrough platform for the advanced engineering of cell lines. The company is committed to improving the production of viral vectors used in gene therapy by combining an innovative bioinformatics platform with advanced R&D experimentation.

Remora Biotech is a biotherapy portfolio company with a track record of successfully turning science into life-changing biotherapies. We focus on high-impact therapeutic areas including oncology, immunology, regenerative / aesthetic medicine and cell and gene therapies.

TIBIO is a Swiss environmental biotechnology and scientific consulting company founded in 2009 and active in the fields of: Scientific consulting and R&D project management. Chemical, microbiological and toxicological analysis. Provision of solutions for environmental pollution problems.

APR Applied Pharma Research s.a. (wholly owned by Relief Therapeutics Holding AG, SIX: RLF.SW), is a B2B Swiss-based international biopharma focused on development and global commercialization of innovative, patent protected products designed to address unmet needs.

At Stämm we develop accessible, plug & play biomanufacture solutions; allowing an automatized, continuous and more efficient production of biologics and cell therapies while managing media conditions. We have reinvented biomanufacturing by providing an alternative to the known biomass production.

Quant Biomarkers develops next-gen urinary biomarkers for cardio-kidney-metabolic diseases. Its RenoRisk™ test detects kidney injury 3–6 years earlier than standard markers, supported by AI software for improved risk stratification, monitoring, and management.

MaxWell Biosystems is an electronics-focused life-science company based in Zurich, Switzerland, developing and selling high-content electrophysiology platforms to help our customers in the pharmaceutical industry and in academia make their drug discovery and research more efficient.

Our mission is to develop novel formulations for biological drugs enabling direct and exclusive delivery to diseased cells and tissues. Our concept for the oligonucleotide drug family of siRNAs creates a broad potential for this new generation of drugs, having recently emerged in the drug landscape.

At ATANIS Biotech AG, our mission is to revolutionize the way allergies are diagnosed and thereby to improve treatment success Our novel cell-based assay allows us to quantify patients allergic status with unparalleled diagnostic accuracy, without needing to expose patients to the culprit allergen.

Salvina Therapeutics is developing antibodies with a novel approach for targeting TNF and TNF superfamily members with the aim of improving their safety and efficacy, and facilitating the generation of novel bispecific therapies.

Oryl Photonics has developed a groundbreaking laboratory instrument for solubility and aggregation measurement. It is the world's first accurate and rapid solubility testing solution that saves precious drug compounds.

ONtrack Biomedical AG is a Swiss spin-off of the University Zurich and University Hospital Zurich which develops in-vitro diagnostic tests for the early and non-invasive detection and monitoring of cancer. Our first product is a urine test for the early detection and monitoring of prostate cancer.

Swiss Deeptech developing AI-driven hardware & software measuring aging hallmarks, starting with telomeres via our single-cell & nucleotide-resolution technologies.We leverage these to generate actionable datasets for diagnostics, stratification and drug discovery in idiopathic age-related diseases.

FinalSpark is at the forefront of technological innovation, pioneering the development of bioprocessors — the next generation of digital processors. These groundbreaking bioprocessors utilize human neurons instead of traditional silicon, marking a significant leap in processing technology.

iCure offers the Cardinal platform for developing digital health applications that comply with cybersecurity standards, with end-to-end encryption, FHIR interoperability, and open-source SDKs, accelerating innovation in e-health. iCure is ISO27001, ISO13485, HDS certified, GDPR and NIS2 compliant.

RDP Pharma (RDP) is a privately held biotech, dedicated to the vision that their products will deliver valuable medicines to patients in need. RDP’s leadership team and board of directors are focused on getting their products into clinical trials and addressing the unmet medical needs of patients.

Altorfer Engineering is a specialized contractor and consulting company. We provide expertise in engineering and project management services, and technology transfers. Our focus is on developing and managing aseptic formulation and fill-finish processes tailored to your receiving sites.

Olgram develops new drugs to cure immune deficiencies for which there are no satisfactory therapeutic solutions. Our 1st clinical application is immunodepression post traumatic brain injury, affecting 5 million people. We also develop new anti-infectious to cure the chronic bacterial infection.

inSEIT solves the challenges of enzyme immobilization and unlocks the potential of immobilized biocatalysts for the production of APIs and chemical intermediates. We use bioinformatic tools to reduce the risk, time and cost associated with biocatalyst development.

Matrix Fine Chemicals is an innovative supplier of speciality fine chemicals and bespoke, complex, multi-step organic synthesis. Since 2001, we are the preferred partner for pharmaceutical, personal care, agrochemical, life science companies of all sizes.

Revolutionizing clinical trials, Trialize's cutting-edge automation platform accelerates study build times by 4x and curbs manual labor by up to 73%, enhancing data quality, patient adherence, and team morale. It's a game-changer in modern, decentralized, and virtual studies.

Swiss Bioscience was established in 2014 in Switzerland and is specialized in producing pharmaceutical quality grade stems cells under cGMP* conditions. The cells are isolated from human adipose tissue to produce SVF which is then purified and expanded to produce hADSCs.

CELLnTEC technologies enable science and industry to develop innovations in stem cell research, regenerative medicine, cell-based therapies, and beyond. The company is a pioneering developer of chemically defined, animal and human components-free precision media.

Caland SA provides a professional, confidential, competitive and impeccable service of pharma-grade CO2 extraction, distillation and cannabis formulation based on GMP requirements. A modern production line, coupled to a qualified ERP, ensures uncompromising quality of all products and services.

We at INCAPTEK are developing advanced drug delivery systems. We deliver drugs at the right place, in the right dosage, and at the right time. Our smart, programmed-shell micro(nano)capsules can be used for controlled and targeted drug delivery for both biotech and medtech.

Curare specializes in translational and clinical pharmacology, increasing confidence in therapeutics translation from the bench to clinical proof‑of‑concept, and enhancing early stage decision-making. Expertise tailored to your needs, from small biotech to pharma.

Our goal is to deliver innovations in health care through cutting-edge tech and research, addressing challenges in antimicrobial therapies to improve patient outcomes. We are committed to delivering superior treatments that promote healing and improve quality of life globally.

Rambam AG is a Swiss-based venture studio and accelerator platform for breakthrough drug discovery and development. Our portfolio of companies and programs is supported by a core group of seasoned industrial experts, PMs and dedicated functional experts from Switzerland, Portugal, Germany and the US.

Floratek Pharma is focused on drug discovery and preclinical development, enhancing the healing power of plants through the optimisation of existing natural compounds. The company pipeline comprises of anti-cancer and neurodegenerative disorder therapies as well as anti-aging dietary enhancements.

I work closely with my clients as a freelance science business development project manager. That said, Boehler Life Science Advice is not a typical consultancy, even though strategic planning and execution are important elements of how I support my clients.  

Qanatpharma (QP) is a Swiss clinical-stage biotech pioneering resistance artery medicine. Our Arteriome platform combines vascular biology, functional phenotyping and AI to discover novel drug targets and develop therapeutics for cardiovascular and neurological diseases.

We are a clinical research team delivering patient-centric clinical investigations across Europe and MENA. We combine strong site access with DCT/hybrid delivery, an integrated digital trial stack (eTMF, eCRF, eCOA, RTSM), and risk-based monitoring to start fast, run clean, and stay audit-ready.

Isospec unlocks the full human metabolome, delivering structurally certain biomarker data that accelerates drug development, diagnostics, and patient stratification.

Orio Therapeutics developed a technology based on protein engineering allowing to integrate a "built-in" delivery systems into any therapeutic protein. Orio Therapeutics has set as a priority for their first product the development of a cardioprotective drug for heart attack patients.

VACCENTIS AG is a Zurich-based investment company focused on the biotech and pharmaceutical sector. The entire research, production and sales activities are carried out by two highly specialized subsidiaries, VCC MEDICAL and FBM-Pharma, which focus on special methods of personalized medicine.

InkVivo Technologies combines its patented biomaterial platform with advanced manufacturing technologies to fabricate novel delivery systems that ensure controlled and prolonged release of active ingredients (e.g., small molecules, biologics and micronutrients).

Outsourcing, Supply Chain & Development Operations Experts and Solutions for Innovative Biotechs & Medtechs. Kisco gives access to teams of seasoned experts to support the development cycle, from Clinical Research (CRO), Supply Chain set up, Outsourced Manufacturing (CMC, CDMO), and R&D Operations

FimmCyte is developing disease modifying therapies for chronic diseases through the direct elimination of diseased cells. FimmCyte has a pipeline of assets two of which are about to begin IND enabling studies, one for endometriosis and the second for organ fibrosis.

Phialogics is a preclinical biotech company specialized in engineering next-generation biologics to rebalance the immune response in acute and chronic inflammation.

Tenpoint Therapeutics is a global, clinical-stage biotech company developing treatments to rejuvenate vision in the aging eye. Its pipeline includes treatments for ophthalmic indications with the greatest need and global market potential, including presbyopia, cataracts and geographic atrophy.

Amphilix AG is a Basel-based biotech developing next-generation radioligand therapies using a proprietary 3D linker platform and small-molecule ligands. Its clinical-stage lead AMX-0053 targets a protein for colorectal cancer and is ready for First-in-Human imaging. The company seeks CHF 9m Seed.

Cetacea Clinical offers Clinical Operations Services and functional services, including trial management, regulatory compliance, data management, and quality oversight. Our robust Quality Management System ensures efficient, high-quality clinical trials from start to finish.

We identified a novel immuno-oncology target through bacterial metabolites that activate tumor-residing macrophages, triggering a potent anti-tumor response. By leveraging natural metabolic processes, we develop small molecule therapies to enhance the body’s native immune defense against cancer.

ACM Biosciences AG is a subsidiary of ACM Biolabs PTE Ltd. Singapore. Its purpose is to internationalise its development activities. It leads all clinical and regulatory activities of its pipeline programs and coordinates business development discussions with potential partners.

We are focusing on worldwide sourcing,distributing and custom manufacturing of fine chemicals, intermediates, ingredients, specialities, niche APIs and NCE’S since 1997.

Cellerys AG is a clinical stage biotechnology company, developing immune tolerance therapeutics for the treatment of multiple sclerosis (MS). Antigenic peptides identified from MS patients are coupled to autologous red blood cells which, when reinfused, restore immune tolerance. in 2021 the company entered a

Yokogawa Electric Corporation is an automation company for the manufacturing industry based on measurement, control, and information technologies. Yokogawa Innovation Switzerland is its subsidiary, and its dedicated mission is R&D in the bioeconomy field based on open innovation.

We are an independent biotech company based in Ticino. We focus on generation, development and characterization of nanobodies produced from proprietary, rationally engineered human libraries relevant to enhance the R&D pipeline of partners and clients.

Alloy Therapeutics is a biotechnology ecosystem company democratizing access to tools, technologies, and services for discovering and developing therapeutic biologics across six modalities, including antibodies, TCRs, genetic medicines, peptides, cell therapy, and drug delivery.

NexMR is a Magritek company providing benchtop NMR solutions to Pharma, Biotech, and Life Science companies. We provide enterprise customer support for benchtop NMR implementation across diverse workflows in the industry: radiochemistry, reaction monitoring, flow chemistry, PAT, screening, and more.

AlphaMol is an AI-based bio-pharmaceutical company focusing on G protein-coupled receptor drug discovery. The co-founders of AlphaMol are leading scientists in the area of GPCRs. Many essential molecular mechanisms and biotechnology were invented by the members of AlphaMol.

PDC Therapeutics is a clinical-stage biotech start-up developing targeted Polymer-Drug Conjugate technologies with an optimal therapeutic index. The proprietary Sagitta® biodegradable conjugation platforms help discover and develop therapies with no compromise with a versatile targeting capability.

Pheida develops and deploys biotech solutions at scale to reduce GHG emissions and other pollutants, and to remediate contaminated soil and water. Pheida products combine advanced biotech, proprietary application engineering to deliver unique and commercially attractive solutions.

Founded in 2018, Peptone specializes in novel therapeutics for Intrinsically Disordered Proteins (IDPs), linked to inflammatory diseases such as cancer. Their approach integrates biophysics, supercomputing, and machine learning, now advancing in their labs.

SEAL Therapeutics develops an innovative gene therapy approach that overcomes the functional defects causing LAMA2-related muscular dystrophy. The approach involves AAV-based delivery of specifically designed artificial linker proteins to compensate for the missing laminin-alpha 2 in muscle fibers.

Thermo Fisher Scientific Lengnau is a state-of-the-art multi-purpose manufacturing facility for the production of biologics. It offers highly flexible biomanufacturing technologies, from development to large-scale production with single use and stainless steel equipment to meet our customer needs.

Whatever your level of maturity regarding the valorization of data in your company, our Luciders are your trusted advisors to design and implement a data roadmap. We will work closely with your different business units to explore how data, advanced analytics, AI and ML can solve complex challenges.

Tigen is a Swiss clinical stage biotech company developing cell therapies to cure cancer. A disruptive catalyst, combining a unique culture with a multidisciplinary set of world-class capabilities and a long-term perspective to accelerate access to novel T-cell therapies for patients and society.

MedXCell is a Swiss biotech venture builder led by entrepreneurs and backed by private investors. MedXCell's portfolio includes pre-clinical companies CYTEA BIO and Soteria Bio.

Landmark BioVentures AG, founded in 2021 and headquartered in Basel, Switzerland, is an integrated and agile biotech hub-and-spoke company. LBV takes a unique model focused on lean operations, smart capital allocation, and diversified nexus of 8 companies developing 12 first-in-class therapeutics.

Solid Drug Development (SDD) is a Strategic and Operational consultancy based in Geneva. The company founded in 2010 is specialized in the development of Biotech and Pharma products.

Elionova AG is a Swiss biotechnology company founded in September 2020. Headquartered in Fribourg, Elionova specializes in the development of cutting-edge immunodiagnostic solutions. Real-Time Immunoassays: Quantitative, Fast (10min to result), Simple (one step) using Disposables.

MPC Therapeutics is the leading biotech company developing Mitochondrial Pyruvate Carrier (MPC) targeted therapies. MPC is an extraordinary target that plays a key role in metabolism. We are committed to delivering novel treatments in cancer immunotherapy, kidney diseases and neurodegeneration.

We are a clinical-stage biotech company developing first-in-class small molecules to induce mitophagy, i.e. the process of replacing damaged mitochondria. We address age-related and chronic diseases including CNS disorders to treat cognitive impairment.

4bases is a company active in the fields of prevention and precision medicine. 4bases is a certified company working accordingly to the IVDR regulation. Our products are reagent kits for platform-independent New Generation DNA Sequencing (NGS), data analysis software and diagnostic protocols.

Somagenetix is a spin-off from the University of Zurich leveraging scientific, clinical & commercial expertise to solve unmet medical needs. With our gene therapy platform, we aim at becoming a leading company with first & best-in-class treatments for phagocyte-related disorders.

Mosanna is committed to improving patient outcomes and quality of life in high unmet need diseases, carefully selecting innovative medicines for further development. Our first goal is to bring an effective and well tolerated medicinal nasal spray to Metabolic Obstructive Sleep Apnea patients.

Adoram is a UNIGE spinoff that is developing next-generation allosteric small molecule drugs targeting A2A receptors for cancer and inflammatory diseases, powered by a proprietary AI-enhanced GPCR discovery platform and in-house screening technologies for rapid, high-quality lead generation.

Aukera Therapeutics is a preclinical stage company developing the first RAPTOR inhibitors, a new approach to selectively modulate the proven target mTORC1. The lead program focuses on genetically-driven epilepsies such as TSC. Future use include age-related and neurodegenerative diseases.

FluoSphera has developed human multi-tissue systems that accurately replicate and analyze how a drug interacts with multiple organs to predict systemic response in humans, i.e. the response at the whole body level — ultimately determining clinical success for patients.

Praed Pharmaceuticals is biopharmaceutical company founded by industry experts. Our mission is to deliver a next generation treatment for Crohn’s disease. We are developing a promising oral compound, cadazolid, for the treatment of Crohn’s disease.

Streefkerk Life Science Consultancy (SLSC) supports small pharmaceutical companies to improve efficiency, comply with regulations and standards, and excel in designing high-quality clinical development plans, to deliver new drugs to patients as soon as safely possible.

Aspeya, owned by Philip Morris International, operates independently and utilizes Fertin Pharma's oral technology platform. Fertin Pharma, a wholly owned subsidiary of Aspeya, is a CDMO that develops and manufactures innovative oral and intra-oral delivery systems.

Biotech in the Autoimmune/Fibrosis Therapeutics Space.

Ymmunobio AG is a preclinical stage biotechnology company developing first in class assets for the treatment of solid tumors.

House of Lab Science provides plug-and-play lab infrastructure for biotech and foodtech startups across Switzerland. Our lab-as-a-service model offers ready-to-move-in, certified, well-equipped and affordable labs, helping teams start fast and scale from day one.

Aurealis Therapeutics is a Swiss-Finnish cell and gene therapy platform company. Our multi-target scalable low COGS products, based on genetically engineered lactic acid bacteria, addresses unmet medical needs: Chronic wounds - diabetic foot ulcers, venous ulcers, pressure ulcers - deadly cancers - ovarian ca

Miltenyi Biotec Swiss AG is the local subsidiary of Miltenyi Biotec BV&Co KG (Germany). Miltenyi Biotec plays an important role in the design, development, manufacture, and integration of products that empower the advancement of biomedical research and enable cell and gene therapy.

Atopia Therapeutics is developing a revolutionary treatment for allergic diseases such as atopic dermatitis, allergic asthma, food allergies and hay fever based on the discovery that a bacterium present in the human stomach produces a protein that protects us from these diseases.

MD Bioproducts, with over 30 years of experience, is a worldwide manufacturer and supplier of high-quality antibodies, reagents, peptides, assays, and disease-induction reagents supporting research in arthritis, autoimmune diseases, immunology, inflammation, neurology, metabolism, and oncology.

Immune response on a chip!

NovaGo Therapeutics focuses on two regeneration promoting therapeutics aimed at restoring nerve fibre connections in acute spinal cord injury(SCI) Ph1b clinical trial for SCI was started in Dec 2024 and successful finslaized. PoC studies planned to start mid 2026.

NXI Therapeutics is committed to creating tomorrow’s disruptive immunotherapies for T cell-mediated autoimmune diseases and transplantation by coronin 1 modulation. NXI’s unique approach enables an auto- & allo-selective immunomodulation that retains immunocompetence against infections and cancer.

ZETA is an end-to-end solution provider and innovation leader for pharma & biotech and specializes in the design, automation, and qualification of customer-specific systems for pharmaceutical manufacturing. ZETA is an EPCMv contractor, drives digtialization and develops decarbonization strategies.

TissueLabs is a Swiss biotech pioneering biofabrication, developing 3D bioprinters, tissue-specific hydrogels, and engineered tissues. Supporting research, drug testing, and regenerative medicine, its long-term vision is to create the first transplantable bioartificial heart.

InCephalo is a preclinical stage biotech company with a compartment locked (CLocked) technology. InCephalo is positioning itself as a CLocked Fc-Fusion Cytokine and antibody company. The company’s most advanced product at a proprietary IL-12 for local application of brain cancers.

therainnova AG provides strategic and operational regulatory affairs consulting for the biopharmaceutical industry in Europe. With expert leadership and a strong partner network, we offer end-to-end regulatory support, including due diligence, to maximize portfolio value.

Limula is a Life Science Tools company based in Lausanne, Switzerland. We combine cell therapy process development and precision engineering to offer a fully closed and automated platform for the production of CAR-T and other highly-personalised treatments.

Healiva’s Wound Care & Skin Diseases proprietary Platform Technology includes an end-to-end approach with enzyme technology and cell therapies for wound care and skin diseases. The platform can diversify into vitiligo management, skin regeneration or sports injury applications.

Bright Peak Therapeutics is a biotechnology company advancing a portfolio of multifunctional immunotherapies. We leverage our world-class protein engineering & conjugation platform to generate novel protein therapeutics for cancer and other indications. Bright Peak is located in Basel and San Diego.

Athebio develops ultra-stable biotherapeutics using proprietary Athebody® DARPin molecules with high affinity and specificity. We partner on radiotherapeutics, T cell engagers, targeted delivery (LNP/AAV/oligo) and affinity ligands, enabling breakthrough therapeutic strategies.

At Alithea Genomics we develop, produce and commercialize cutting-edge solutions for drug and biomarker discovery based on gene expression. Our products provide high throughput and cost-efficiency, which is ideal for large-scale projects such as drug screening and biomarker discovery.

Noema Pharma is a clinical-stage biotech pioneering a portfolio of disease-transforming therapeutics for CNS-mediated conditions.

Adiposs is a medtech start-up company, a spin-off of the University of Geneva, developing medical imaging products and technologies.

EsoCap AG is developing a unique targeted delivery platform technology for the treatment of patients with diseases of the esophagus. EsoCap recently successfully completed the double-blind, randomised, placebo-controlled Phase II ACESO study in the lead indication eosinophilic esophagitis (EoE).

Labatec is a privately owned Swiss-based pharmaceutical company with more than 50 years of experience in delivering high quality products to the European and Emerging Markets. Covering both the hospital and retail sectors, we have a portfolio of over 65 products and a growing geographic footprint.

AMYRA is developing a unique enzyme combination for curative care of Celiac Disease and Non-Celiac Gluten Sensitivity (NCGS), which represent major public health issues. AMYRA’s products have the potential to establish the standard of care and majorly impact the lives of affected people.